[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( [61fa9913e01c...] --------------------------------------------------------------- [707% Growth For American Lithium Company After They Fight Back Against China]( [They've Already Seen 707% Growth In 2021, And That Could Just Be The Start]([aff_i?offer_...] --------------------------------------------------------------- July 8, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers from all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- ["The Most Critical Metal for Global Economies"]( [e33a456c-e65...](The soaring demand for this "red rock" may be the most important development in 2022. It's key in the transition to the new green energy economies. Bloomberg News warns… "Within a decade, the world may face a massive shortfall of what's arguably the most critical metal for global economies." Copper prices have nearly doubled in the past year. [Find Out How This Is Good News for Commodity Investors.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Avadel Pharmaceuticals, AVDL]( Recent Analyst Action: Ami Fadia, analyst at Needham, reiterates coverage on [Avadel Pharmaceuticals (AVDL)](in the Healthcare sector with a Buy rating and a price target of $6 (1 week ago). - Recent Price: $$4.63 - Average Analyst Price Target: $10.60 (128.94%) - Market Cap: $$252.96M [TipRanks.com]( also reports that [Avadel Pharmaceuticals](currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $10.60. The target pricing ranges from a high forecast of $19.00 down to a low forecast of $2.00. [Avadel Pharmaceuticals (AVDL)](’s last closing price was $$4.63 which would put the average price target at $$10.60. Here are 3rd party ratings for [AVDL](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Top 36% (89 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Write These Three Ticker Symbols Down]( [5541affc-43f...](According to millionaire trader Jeff Clark, the stocks marked in this proprietary calendar are pre-determined to see big moves any day… all thanks to federal law 73-291. In his testing, he already doubled his money in 45 minutes with this strategy. And now he revealed the names of three of those stocks, completely free. [Click here to see the details and write them down.]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [Microstrategy, MSTR]( Recent Analyst Action: Brent Thill, analyst at Jefferies, reiterates coverage on [Microstrategy (MSTR)](in the Technology sector with a Hold rating and a price target of $215 (2 weeks ago). - Recent Price: $$229.25 - Average Analyst Price Target: $539.33 (135.26%) - Market Cap: $$2.48B [TipRanks.com]( also reports that [Microstrategy](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $539.33. The target pricing ranges from a high forecast of $950.00 down to a low forecast of $215.00. [Microstrategy (MSTR)](’s last closing price was $$229.25 which would put the average price target at $$539.33. Here are 3rd party ratings for [MSTR](: - TipRanks.com: Strong Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Strong Sell, Bottom 40% (150 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Verrica Pharmaceuticals, VRCA]( Recent Analyst Action: Serge Belanger, analyst at Needham, reiterates coverage on [Verrica Pharmaceuticals (VRCA)](in the Healthcare sector with a Hold rating (1 week ago). - Recent Price: $$3.19 - Average Analyst Price Target: $11.50 (260.50%) - Market Cap: $$119.35M [TipRanks.com]( also reports that [Verrica Pharmaceuticals](currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $11.50. The target pricing ranges from a high forecast of $16.00 down to a low forecast of $4.00. [Verrica Pharmaceuticals (VRCA)](’s last closing price was $$3.19 which would put the average price target at $$11.50. Here are 3rd party ratings for [VRCA](: - TipRanks.com: Moderate Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Buy, Top 36% (89 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [I Need YOUR Help Finding America's Next Iconic Companies]( [9d3fa8e6-37d...](Hey, it’s Daymond John – “The People’s Shark.” I’m on a mission to find “the next” Microsoft, Apple, and Tesla. But I can’t do it alone, so I’m assembling a team of rockstars to help me. [Join me here.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Oramed Pharmaceuticals, ORMP]( Recent Analyst Action: Nathan Weinstein, analyst at Aegis Capital, reiterates coverage on [Oramed Pharmaceuticals (ORMP)](in the Healthcare sector with a Buy rating and a price target of $30 (1 month ago). - Recent Price: $$7.24 - Average Analyst Price Target: $31.00 (328.18%) - Market Cap: $$219.04M [TipRanks.com]( also reports that [Oramed Pharmaceuticals](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $31.00. The target pricing ranges from a high forecast of $32.00 down to a low forecast of $30.00. [Oramed Pharmaceuticals (ORMP)](’s last closing price was $$7.24 which would put the average price target at $$31.00. Here are 3rd party ratings for [ORMP](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: n/a, n/a [Click here for chart >>]( -------------------------------------------------------------------------- [Cardiff Oncology, CRDF]( Recent Analyst Action: Joseph Catanzaro, analyst at Piper Sandler, reiterates coverage on [Cardiff Oncology (CRDF)](in the Healthcare sector with a Buy rating and a price target of $7 (1 month ago). - Recent Price: $$3.23 - Average Analyst Price Target: $12.67 (292.26%) - Market Cap: $$135.11M [TipRanks.com]( also reports that [Cardiff Oncology](currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $12.67. The target pricing ranges from a high forecast of $22.00 down to a low forecast of $7.00. [Cardiff Oncology (CRDF)](’s last closing price was $$3.23 which would put the average price target at $$12.67. Here are 3rd party ratings for [CRDF](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 31% (78 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Notorious "Crypto Hater" drops bombshell: "Don't buy ANY Bitcoin before you see this expose..."]( [76d060da-aa0...](Millionaire Trader who managed $200 Million for the Silicon Valley Elite reveals, for the first time ever… "How I trade Bitcoin* - using my stock brokerage account - for the chance to make 3-times... 5-times... even 10-times more money than any of the crypto HODLERs out there!" *No crypto wallets or crypto exchanges are needed... No previous experience. This 3-second “Boomer” crypto move works whether Bitcoin goes up or down. [Click here - this LIVE demonstration reveals how he does it.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Oak Street Health, OSH]( Recent Analyst Action: Kevin Fischbeck, analyst at Bank of America Securities, reiterates coverage on [Oak Street Health (OSH)](in the Healthcare sector with a Sell rating and a price target of $18 (3 weeks ago). - Recent Price: $$23.7 - Average Analyst Price Target: $27.09 (14.30%) - Market Cap: $$5.76B [TipRanks.com]( also reports that [Oak Street Health](currently has 12 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $27.09. The target pricing ranges from a high forecast of $33.00 down to a low forecast of $18.00. [Oak Street Health (OSH)](’s last closing price was $$23.7 which would put the average price target at $$27.09. Here are 3rd party ratings for [OSH](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Bottom 33% (168 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [CS Disco, LAW]( Recent Analyst Action: Doug Bruehl, analyst at J.P. Morgan, reiterates coverage on [CS Disco (LAW)](in the Technology sector with a Buy rating and a price target of $55 (1 month ago). - Recent Price: $$24.86 - Average Analyst Price Target: $38.00 (52.86%) - Market Cap: $$1.41B [TipRanks.com]( also reports that [CS Disco](currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $38.00. The target pricing ranges from a high forecast of $55.00 down to a low forecast of $28.00. [CS Disco (LAW)](’s last closing price was $$24.86 which would put the average price target at $$38.00. Here are 3rd party ratings for [LAW](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Bottom 44% (139 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Copper More Critical than Lithium?]( [be7e813c-17c...](Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found. [See How You Can Benefit From New Copper Discoveries.](//trailer.web-view.net/Links/0X05435F93DBB55B75A33ACDAA1C67F99F276F65FC01B34EACA8782282AECB43A462788D4C43C01978B0AB7C7814A73417BC3948C072B4299ED5204FCFBC5BDF4F58817A62CDD4649F.htm [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- And there you have it--7 Five Day Gainers. Sincerely, Editor, DailyMarketMovers.com Newsletter Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Sandpiper Marketing Group, LLC | PO Box 407 | Mount Mourne | North Carolina | 28123 | United States | 8458030954 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software